When standard cancer treatments don’t work, or if doctors can’t determine where a patient’s cancer originated, genomic sequencing can help pinpoint mutations in a tumor that might be matched with medicines targeting those specific alterations.
Under normal circumstances, our immune system naturally helps our bodies fight off germs and disease, keeping us healthy. However, cancer cells are often invisible to our immune system which means our bodies can’t detect the disease in order to fight it. This is one reason cancer can be difficult to treat.
Immunotherapy researchers have discovered how a subset of T cells known as memory T cells are generated in melanoma survivors with vitiligo and able to function for years after a tumor is gone.
To protect your safety, researchers must go through many steps to prove the treatment or intervention being studied is as safe as possible and might be better than standard treatments. This starts with many years of research in the lab, looking at how the treatment works in cells and animals.
New technologies and large, “-omics” datasets are now allowing researchers to examine shared features not just within a single type of cancer — such as breast cancer — but to look for patterns across many types of cancer.
The MyProstateScore test measures levels of cancer-specific genes in a patient’s urine. It's based on U-M research that half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together -- creating an on-switch for prostate cancer development.
The modeling study looks at the benefits and harms associated with various low-dose computed tomography screening strategies—identifying those that result in the most benefits for a given level of screening.
Beginning March 15, 2021 the mechanical system controlling the infusion pharmacy within the cancer center building will undergo corrective renovation. The planned reopening of the Rogel infusion pharmacy is May 3.
MENU
